Search results

1 – 10 of 117
Article
Publication date: 24 October 2023

Hassan Bruneo, Emanuela Giacomini, Giuliano Iannotta, Anant Murthy and Julien Patris

Biotech companies stand as key actors in pharmaceutical innovation. The high risk and long timelines inherent with their R&D investments might hinder their access to funding…

Abstract

Purpose

Biotech companies stand as key actors in pharmaceutical innovation. The high risk and long timelines inherent with their R&D investments might hinder their access to funding, potentially stifling innovation. This study aims to explore into the appeal of biotech companies to capital market investors, whose financial backing could bolster the growth of the biotechnology sector.

Design/methodology/approach

This paper uses a dataset of 774 US publicly listed biotech firms to investigate their risk and return characteristics by comparing them to pharmaceutical firms and a sample of matched non-biotech R&D-intensive firms over the sample period 1980–2021. Tests show that the conclusions remain consistent across diverse methodological approaches.

Findings

The paper shows that biotech companies are riskier than the average firm in the market index but outperform on a risk-adjusted basis both the market and a matched group of R&D-intensive firms. This is particularly true for large capitalization biotech, which is also shown to provide a diversification benefit by reducing the downside risk in past crisis periods.

Originality/value

This paper provides insight relevant to the current debate about the overall performance of the biotech industry in terms of policy changes and their impact on small, early-stage biotech firms. While small and early-stage biotech firms are playing an increasing role in scientific innovation, this study confirms their greater vulnerability to financial risks and the importance of access to capital markets in enabling those companies to survive and evolve into larger biotech.

Details

International Journal of Productivity and Performance Management, vol. ahead-of-print no. ahead-of-print
Type: Research Article
ISSN: 1741-0401

Keywords

Book part
Publication date: 11 July 2023

Felix Barahona Márquez, Susana Domingo Pérez and Ernest Solé Udina

This chapter focuses on the relationship between biotechnology start-ups and larger pharmaceutical corporations when they work as partners in innovation strategic alliances. For…

Abstract

This chapter focuses on the relationship between biotechnology start-ups and larger pharmaceutical corporations when they work as partners in innovation strategic alliances. For three decades, these companies have become major players in innovation in the health sector. This means that the development of many products is a result of the cooperation they carry out. However, due to the great differences between these companies, certain problems can often arise. More specifically, our analysis explores the perceptions of the achievement expected by each partner. This is an important aspect to determine the satisfaction of these firms among strategic alliance. The authors follow qualitative methods to address the topic, conducting personal interviews with managers of these companies. Our findings reveal the concrete facts that can prevent reaching the proposed goals of these partners as well as stress the crucial importance of the human aspect to mitigate potential problems.

Details

Collective Entrepreneurship in the Contemporary European Services Industries: A Long Term Approach
Type: Book
ISBN: 978-1-80117-950-8

Keywords

Article
Publication date: 21 June 2021

Shantala Samant, Pooja Thakur-Wernz and Donald E. Hatfield

The purpose of this paper is to study the differences in the internationalization process of firms from emerging economies and the impact of their international expansion related…

Abstract

Purpose

The purpose of this paper is to study the differences in the internationalization process of firms from emerging economies and the impact of their international expansion related choices on the nature of technological innovations developed by these firms. Specifically, the authors compare two principal perspectives on internationalization – the incremental internationalization process (slow, gradually increasing commitments using greenfield investments to similar host countries) and the springboard perspective (aggressive, rapidly increasing commitments using mergers and acquisitions to advanced host countries).

Design/methodology/approach

Building on key differences between the incremental internationalization and springboard perspectives, the authors argue that differences in the speed and mode of entry, as well as the interaction between the mode of entry and location of internationalization, will lead to differences in the types of technologies (mature versus novel) developed by emerging economy firms. The authors examine the hypotheses using panel data from 1997 to 2013 on emerging economy multinationals (EMNEs) from the Indian bio-pharmaceutical industry.

Findings

The findings suggest that firms internationalizing at higher speeds and using cross-border M&As tend to have innovations in mature technologies. The interesting findings can be explained by the challenges faced by emerging economy firms in experiential learning and the assimilation of external knowledge. In addition, the authors find that internationalization to technologically advanced countries weakens the relationship between cross-border M&As and innovation in mature technologies, suggesting that direct learning from technologically advanced environments may help alleviate the assimilation challenges of cross-border M&As.

Originality/value

The authors advance literature on EMNE internationalization by comparing the impact of their choice of internationalization approaches (incremental internationalization or springboard approach) on their innovation performance. The authors contribute to literature on EMNEs that has focused on the determinants of internationalization by identifying the learning implications of internationalization. The authors contribute to the nascent stream of literature on the level of innovation and catching up by EMNEs by performing a fine-grained analysis of the nature of technology innovation.

Article
Publication date: 19 May 2022

Amina Toumi, Rim El Khoury, Etienne Harb and Nohade Nasrallah

This study models the effects of the COVID-19 pandemic on the performance of the private health-care sector in the Middle East and North Africa (MENA) countries. This paper aims…

Abstract

Purpose

This study models the effects of the COVID-19 pandemic on the performance of the private health-care sector in the Middle East and North Africa (MENA) countries. This paper aims to address the economic, societal and sustainability of the health-care sector.

Design/methodology/approach

Data were collected from Bloomberg and the sample consists of 534 firm-year observations from 55 firms listed over 2010–2020. The authors apply panel data and control for the country and governance effects.

Findings

The authors found heterogeneous results regarding the three sub-sectors. The pandemic has a negative effect on the accounting and market performances of the “Pharmaceutical companies” and an insignificant impact on “Healthcare Management and Facilities Services.” Moreover, the impact of COVID-19 on health-care firms’ performance depends on the country’s economic classification and the degree of regulatory and governance frameworks.

Research limitations/implications

Further studies may consider a larger sample and other regions. It is recommended to address the health-care sector's challenges to invest in new technologies such as “digital twin” and predictive and personalized medicine. It is worth testing model development theory and its effects on speeding up and designing models to ensure the proper functioning and developing mathematics to determine uncertainties in patient data and model predictions.

Originality/value

To the best of the authors’ knowledge, this paper is novel as it is unique in modeling the impact of COVID-19 on the health-care public companies in the MENA region. The findings pinpoint firms’ and countries’ heterogeneous impacts on financial and market performances.

Details

Journal of Modelling in Management, vol. 18 no. 4
Type: Research Article
ISSN: 1746-5664

Keywords

Article
Publication date: 10 May 2022

Anurag Mishra, Pankaj Dutta, S. Jayasankar, Priya Jain and K. Mathiyazhagan

This paper presents a systematic literature review of the various aspects of reverse logistics (RL) and closed-loop supply chains (CLSC) in implementing and achieving circular…

2822

Abstract

Purpose

This paper presents a systematic literature review of the various aspects of reverse logistics (RL) and closed-loop supply chains (CLSC) in implementing and achieving circular economy (CE) motives. CE is identified as a method of embracing imperishability into the economic structure, helping shift from a linear to a condition leading to ecological and social benefits.

Design/methodology/approach

Systematic literature was used to review a total of 80 peer-reviewed articles are included in the study and covers different concepts related to the implementation of CE, such as cost-saving, network design, sustainable RL, waste management and extended producer responsibility.

Findings

The findings reveal that the research in the domain is in a growing phase, and in recent years, a lot of attention has been given by researchers across the globe. However, further research is required in crucial areas for the adoption of CE, such as retail reverse logistics, pharmaceutical industries and resource recycling industry.

Practical implications

The study discusses the business needs and solutions for industries. Key enablers and barriers are listed along with the main activities involved in each sector in CLSC. Managers can design a pathway to decide which lever to use to overcome a particular challenge.

Originality/value

The work contributes theoretically by developing research themes in RL and CLSC practices applied to CE. It also provides theoretical and practical implications of the study, which can be used as a signboard for further research.

Details

Benchmarking: An International Journal, vol. 30 no. 3
Type: Research Article
ISSN: 1463-5771

Keywords

Article
Publication date: 8 November 2022

Arif Ibne Asad and Boris Popesko

The COVID-19 pandemic creates inefficiencies in the health-care system by having devastating consequences. It has demonstrated how inefficiencies in the health system can have a…

Abstract

Purpose

The COVID-19 pandemic creates inefficiencies in the health-care system by having devastating consequences. It has demonstrated how inefficiencies in the health system can have a significant impact on social cohesion, economic growth and public confidence in government. The main purpose of this study is to explore the contemporary challenges faced by the pharmaceutical industry in Europe.

Design/methodology/approach

This study used a systematic literature review method and adopted inclusion and exclusion criteria after constructive reviews of articles from Web of Science and Scopus databases along with the ranked journals in the Chartered Association of Business Schools to search the following key terms “challenges in the European pharmaceutical industry” during the period from 2011 to 2022. The terms are set to be searched in the publications’ titles, abstracts and keywords.

Findings

This study reviewed 57 papers, and the systematic review revealed the vulnerability of the European pharmaceutical industry, such as the default patent system, ineffective research and development, debate on the role of alliances, low level of expertise in the European health-care system, pharmaceutical supply chain management and other issues.

Research limitations/implications

This study suggests that future research may explore the challenges of multisectoral and cross-country perspectives to get a better understanding, and for the long-term sustainability of public pharmaceutical spending, new models of enhancing research investments are needed, and Europe can still play a leading role in its tradition structure within capturing innovative ideas.

Practical implications

It provides new useful insights to policymakers, global leaders and managers to devise policies to achieve a performance-oriented culture in their institutions and firms.

Social implications

The pharmaceutical sector has recognized the influence of social determinants of health. It moves toward sustained sound health of people to have a flourishing pharmaceutical sector.

Originality/value

There is an insufficient study on the contemporary challenges of the European pharmaceutical industry. This study presents the argument that earlier studies ignored the contemporary issues facing the European pharmaceutical industry from a comprehensive and wider angle. In addition, the COVID-19 pandemic is a recent occurrence, and it causes inefficiency in the health-care sector, where the pharmaceutical industry plays a crucial role; importantly, this topic is emerging and underresearched in the existing literature. There is also a lack of systematic literature review studies in this field.

Details

Measuring Business Excellence, vol. 27 no. 2
Type: Research Article
ISSN: 1368-3047

Keywords

Article
Publication date: 3 January 2022

Jindrich Spicka

Innovation ecosystems face many environmental challenges. The literature review shows that innovation ecosystems accelerate innovation activity, but empirical studies have not…

Abstract

Purpose

Innovation ecosystems face many environmental challenges. The literature review shows that innovation ecosystems accelerate innovation activity, but empirical studies have not provided enough case studies focusing on the minimum-waste business strategy as one aspect of the circular economy. Various forms of interaction between members occur in the innovation ecosystems, which determines the level of cooperation. This paper aims to show the structure and forms of cooperation in an innovation ecosystem using the Czech Hemp Cluster (CHC) and its surroundings and suggest research directions in the field of interaction between members in an innovation ecosystem. Although hemp is associated with the production and distribution of narcotics, it is a versatile plant supporting the minimum-waste business strategy.

Design/methodology/approach

The research is based on a theoretical part of a literature review of major scientific articles on innovation ecosystems from 2016 to 2021. The case study of the CHC and the hemp ecosystem is based on qualitative research in the form of a content analysis of the mission of the cluster members. In addition to content analysis, the classic multidimensional scaling method and hierarchical cluster analysis were used to reveal ecological guilds.

Findings

The case study highlighted the specific relationship between the cluster and the ecosystem. The cluster does not determine the ecosystem boundaries, but the ecosystem is a much broader system of cooperation and interaction between organisations. Clusters emerge after an ecosystem has existed for a particular time to coordinate collaboration and information between organisations and stakeholders. The analysis of the CHC revealed the specific role of non-profit organisations (NPOs) in the innovation ecosystem. NPOs are not engaged in primary functions in the value chain, but they provide supporting activities through coordinated networking, disseminating information on innovation, awareness-raising and stakeholder education. Compared to natural ecosystems, innovation ecosystems are typically characterised by higher forms of collaboration between members.

Research limitations/implications

An exciting opportunity for research on innovation ecosystems is the ecological guilds taken from natural ecosystems and whose identification can help define the boundaries of innovation ecosystems. An opportunity for further research is the comparison of NPO-based and government-based clusters playing a central role in developing innovation ecosystems. Regarding the problematic generalisability of the case study to the entire agricultural production, a challenge is a search for minimum-waste business models in agriculture characterised by the biological nature of production.

Originality/value

Theoretical and empirical studies have not yet considered innovation ecosystems in the minimum-waste context to a sufficient extent. The paper builds on previous scholarly studies focusing on innovation ecosystems and, for the first time, discusses the role of NPOs in the innovation ecosystem. The CHC case study adds a suitable minimum-waste business model to the still very scarce literature on sustainable innovation ecosystems. The article discusses the purpose and forms of cooperation in an innovation ecosystem, identifies a complementarity of roles in the innovation cluster and describes the interrelationship between the cluster and the ecosystem. Discussion of the ecosystem leader in the cluster-based innovation ecosystem shows the differences between Czech, Polish and German life science ecosystems.

Details

International Journal of Emerging Markets, vol. 18 no. 10
Type: Research Article
ISSN: 1746-8809

Keywords

Article
Publication date: 16 February 2023

David Francas, Stephan Mohr and Kai Hoberg

Disruptions and shortages of drugs have become severe problems in recent years, which has triggered strong media and public interest in the topic. However, little is known about…

Abstract

Purpose

Disruptions and shortages of drugs have become severe problems in recent years, which has triggered strong media and public interest in the topic. However, little is known about the factors that can be associated with the increased frequency of shortages. In this paper, the authors analyze the drivers of drug shortages using empirical data for Germany, the fourth largest pharmaceutical market.

Design/methodology/approach

The authors use a dataset provided by the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte [BfArM]) with 425 reported shortages for drug substances (DSs) in the 24-month period between May 2017 and April 2019 and enrich the data with information from additional sources. Using logistic and negative binomial regression models, the authors analyze the impact of (1) market characteristics, (2) drug substance characteristics and (3) regulatory characteristics on the likelihood of a shortage.

Findings

The authors find that factors like market concentration, patent situation, manufacturing processes or dosage form are significantly associated with the odds of a shortage. The authors discuss the implications of these findings to reduce the frequency and severity of shortages.

Originality/value

The authors contribute to the empirical research on drug shortages by analyzing the impact of market characteristics, DS characteristics and regulatory characteristics on the reported shortages. The authors’ analysis provides a starting point for better prioritizing efforts to strengthen drug supply as it is currently intensely discussed healthcare authorities.

Details

International Journal of Operations & Production Management, vol. 43 no. 10
Type: Research Article
ISSN: 0144-3577

Keywords

Article
Publication date: 26 March 2024

Valérie Mérindol and David W. Versailles

Innovation management in the healthcare sector has undergone significant evolutions over the last decades. These evolutions have been investigated from a variety of perspectives…

Abstract

Purpose

Innovation management in the healthcare sector has undergone significant evolutions over the last decades. These evolutions have been investigated from a variety of perspectives: clusters, ecosystems of innovation, digital ecosystems and regional ecosystems, but the dynamics of networks have seldom been analyzed under the lenses of entrepreneurial ecosystems (EEs). As identified by Cao and Shi (2020), the literature is silent about the organization of resource allocation systems for network orchestration in EEs. This article investigates these elements in the healthcare sector. It discusses the strategic role played by entrepreneurial support organizations (ESOs) in resource allocation and elaborates on the distinction between sponsored and nonsponsored ESOs in EEs. ESOs are active in network orchestration. The literature explains that ESOs lift organizational, institutional and cultural barriers, and support entrepreneurs' access to cognitive and technological resources. However, allocation models are not yet discussed. Therefore, our research questions are as follows: What is the resource allocation model in healthcare-related EEs? What is the role played by sponsored and nonsponsored ESOs as regards resource allocation to support the emergence and development of EEs in the healthcare sector?

Design/methodology/approach

The article offers an explanatory, exploratory, and theory-building investigation. The research design offers an abductive research protocol and multi-level analysis of seven (sponsored and nonsponsored) ESOs active in French healthcare ecosystems. Field research elaborates on semi-structured interviews collected between 2016 and 2022.

Findings

This article shows explicit complementarities between top-down and bottom-up resource allocation approaches supported by ESOs in the healthcare sector. Despite explicit originalities in each approach, no network orchestration model prevails. Multi-polar coordination is the rule. Entrepreneurs' access to critical technological and cognitive resources is based on resource allocation modalities that differ for sponsored versus nonsponsored ESOs. Emerging from field research, this research also shows that sponsored and nonsponsored ESOs manage their roles in different ways because they confront original issues about organizational legitimacy.

Originality/value

Beyond the results listed above, the main originalities of the paper relate to the instantiation of multi-level analysis operated during field research and to the confrontation between sponsored versus nonsponsored ESOs in the domain of healthcare-related innovation management. This research shows that ESOs have practical relevance because they build original routes for resource allocation and network orchestration in EEs. Each ESO category (sponsored versus nonsponsored) provides original support for resource allocation. The ESO's legitimacy is inferred either from the sponsor or the services delivered to end-users. This research leads to propositions for future research and recommendations for practitioners: ESO managers, entrepreneurs, and policymakers.

Details

International Journal of Entrepreneurial Behavior & Research, vol. ahead-of-print no. ahead-of-print
Type: Research Article
ISSN: 1355-2554

Keywords

Book part
Publication date: 13 April 2023

Lyailya Maratovna Mutaliyeva and Ulf Henning Richter

Bioenergy remains the largest branch of renewable energy, and microalgae are a promising object of research among other types of biomasses whose scale for energy purposes is…

Abstract

Bioenergy remains the largest branch of renewable energy, and microalgae are a promising object of research among other types of biomasses whose scale for energy purposes is increasing. On the other hand, the growth of global energy production and urbanization, which results in high rates of municipal waste and wastewater generation, requires the development of integrated technologies that allow waste to be disposed of as fully as possible. Sustainable investments in the production of energy by various technologies are one of the methods to solve this complex problem. In this chapter, we study the methods of microalgae utilization of nutrients from wastewater and by-product liquid waste of sustainable investments from microalgae by hydrothermal liquefaction (HTL) technology. Wastewater has a complex composition, and the treatment of nitrogen and phosphorus and other biogenic elements, as well as heavy metals, using biological objects is optimal and cost-effective. Also the water phase after HTL is a by-product that has limited energy value. Biofuel investments have higher growth rates and at the same time do not compete with the investments in fossil fuels. Biofuel investments' cost of seaweed fuel can be reduced through high-value-added related products, such as food and feed additives, and pharmaceutical and cosmetic products.

1 – 10 of 117